-
Tata Capital Share: Bull Case vs Bear Case for 2026
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
No Comments
Tata Capital bull case and bear case for 2026, based on CMP Rs 371.85, 52 week range Rs 296.00 to Rs 390.20, valuation and technical data.
-
Sumitomo Chemical India Share: Bull Case vs Bear Case for 2026
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Sumitomo Chemical India bull case and bear case for 2026, based on CMP Rs 498.35, 52 week range Rs 362.60 to Rs 617.45, valuation and technical data.
-
Tata Chemicals Share: Bull Case vs Bear Case for 2026
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Tata Chemicals bull case and bear case for 2026, based on CMP Rs 641.35, 52 week range Rs 580.30 to Rs 1,026.65, valuation and technical data.
-
Suven Life Sciences Share: Bull Case vs Bear Case for 2026
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Suven Life Sciences bull case and bear case for 2026, based on CMP Rs 378.35, 52 week range Rs 124.11 to Rs 403.35, valuation and technical data.
-
Is GAIL India a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Neeraj Pandey
- Category: Market
GAIL India Q1 FY27: revenue Rs 41,198 crore, PAT Rs 4,671 crore. Full results breakdown and whether the stock is a buy at current levels.
-
Is Eternal a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Kunal Singla
- Category: Market
Eternal Q1 FY27: revenue Rs 20,211 crore, PAT Rs 92 crore. Full results breakdown and whether the stock is a buy at current levels.
-
Sundaram Finance Share: Bull Case vs Bear Case for 2026
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
Sundaram Finance bull case and bear case for 2026, based on CMP Rs 4,578.00, 52 week range Rs 4,000.00 to Rs 5,642.00, valuation and technical data.
-
What to Check Before Acting on a Univest Stock Insight
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
A short checklist to run before acting on a Univest stock insight, from valuation to your own portfolio fit.
-
Is Global Health a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Neeraj Pandey
- Category: Market
Global Health Q1 FY27: revenue Rs 1,304 crore, PAT Rs 157 crore. Full results breakdown and whether the stock is a buy at current levels.
-
Is Godrej Properties a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Neeraj Pandey
- Category: Market
Godrej Properties Q1 FY27: revenue Rs 1,345 crore, PAT Rs 349 crore. Full results breakdown and whether the stock is a buy at current levels.